Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment

Roy H. Perlis, David Mischoulon, Jordan W. Smoller, Yu-Jui Yvonne Wan, Stefania Lamon-Fava, Keh Ming Lin, Jerrold F. Rosenbaum, Maurizio Fava

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

Background: The short (S) allele of the serotonin transporter gene-linked polymorphic region (5HTTLPR) has been associated with poorer antidepressant response in major depressive disorder (MDD) and with antidepressant-induced mania. This study investigated a possible association with treatment-emergent insomnia or agitation. Methods: Thirty-six outpatients with MDD were genotyped at 5HTTLPR and treated with open-label fluoxetine up to 60 mg/day. Treatment-emergent adverse effects were assessed at each study visit. Results: Of nine subjects homozygous for the "S" allele, seven (78%) developed new or worsening insomnia, versus 6 of 27 (22%) non-"S"-homozygous subjects (Fisher's exact p = .005). Similarly, six of nine subjects homozygous for the "S" allele (67%) developed agitation, versus 2 of 27 (7%) of non-"S"-homozygous subjects (Fisher's exact p = .001). Conclusions: The "S" allele of the 5HTTLPR may identify patients at risk for developing insomnia or agitation with fluoxetine treatment. This preliminary result requires confirmation in larger samples.

Original languageEnglish (US)
Pages (from-to)879-883
Number of pages5
JournalBiological Psychiatry
Volume54
Issue number9
DOIs
StatePublished - Nov 1 2003

Fingerprint

Serotonin Plasma Membrane Transport Proteins
Fluoxetine
Sleep Initiation and Maintenance Disorders
Alleles
Major Depressive Disorder
Antidepressive Agents
Therapeutics
Bipolar Disorder
Outpatients
Genes

Keywords

  • Adverse event
  • Agitation
  • Depression
  • Fluoxetine
  • Insomnia
  • Serotonin transporter

ASJC Scopus subject areas

  • Biological Psychiatry

Cite this

Perlis, R. H., Mischoulon, D., Smoller, J. W., Wan, Y-J. Y., Lamon-Fava, S., Lin, K. M., ... Fava, M. (2003). Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biological Psychiatry, 54(9), 879-883. https://doi.org/10.1016/S0006-3223(03)00424-4

Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. / Perlis, Roy H.; Mischoulon, David; Smoller, Jordan W.; Wan, Yu-Jui Yvonne; Lamon-Fava, Stefania; Lin, Keh Ming; Rosenbaum, Jerrold F.; Fava, Maurizio.

In: Biological Psychiatry, Vol. 54, No. 9, 01.11.2003, p. 879-883.

Research output: Contribution to journalArticle

Perlis, RH, Mischoulon, D, Smoller, JW, Wan, Y-JY, Lamon-Fava, S, Lin, KM, Rosenbaum, JF & Fava, M 2003, 'Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment', Biological Psychiatry, vol. 54, no. 9, pp. 879-883. https://doi.org/10.1016/S0006-3223(03)00424-4
Perlis, Roy H. ; Mischoulon, David ; Smoller, Jordan W. ; Wan, Yu-Jui Yvonne ; Lamon-Fava, Stefania ; Lin, Keh Ming ; Rosenbaum, Jerrold F. ; Fava, Maurizio. / Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. In: Biological Psychiatry. 2003 ; Vol. 54, No. 9. pp. 879-883.
@article{a4d7ee29fa704f96bf812dc077899813,
title = "Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment",
abstract = "Background: The short (S) allele of the serotonin transporter gene-linked polymorphic region (5HTTLPR) has been associated with poorer antidepressant response in major depressive disorder (MDD) and with antidepressant-induced mania. This study investigated a possible association with treatment-emergent insomnia or agitation. Methods: Thirty-six outpatients with MDD were genotyped at 5HTTLPR and treated with open-label fluoxetine up to 60 mg/day. Treatment-emergent adverse effects were assessed at each study visit. Results: Of nine subjects homozygous for the {"}S{"} allele, seven (78{\%}) developed new or worsening insomnia, versus 6 of 27 (22{\%}) non-{"}S{"}-homozygous subjects (Fisher's exact p = .005). Similarly, six of nine subjects homozygous for the {"}S{"} allele (67{\%}) developed agitation, versus 2 of 27 (7{\%}) of non-{"}S{"}-homozygous subjects (Fisher's exact p = .001). Conclusions: The {"}S{"} allele of the 5HTTLPR may identify patients at risk for developing insomnia or agitation with fluoxetine treatment. This preliminary result requires confirmation in larger samples.",
keywords = "Adverse event, Agitation, Depression, Fluoxetine, Insomnia, Serotonin transporter",
author = "Perlis, {Roy H.} and David Mischoulon and Smoller, {Jordan W.} and Wan, {Yu-Jui Yvonne} and Stefania Lamon-Fava and Lin, {Keh Ming} and Rosenbaum, {Jerrold F.} and Maurizio Fava",
year = "2003",
month = "11",
day = "1",
doi = "10.1016/S0006-3223(03)00424-4",
language = "English (US)",
volume = "54",
pages = "879--883",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier USA",
number = "9",

}

TY - JOUR

T1 - Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment

AU - Perlis, Roy H.

AU - Mischoulon, David

AU - Smoller, Jordan W.

AU - Wan, Yu-Jui Yvonne

AU - Lamon-Fava, Stefania

AU - Lin, Keh Ming

AU - Rosenbaum, Jerrold F.

AU - Fava, Maurizio

PY - 2003/11/1

Y1 - 2003/11/1

N2 - Background: The short (S) allele of the serotonin transporter gene-linked polymorphic region (5HTTLPR) has been associated with poorer antidepressant response in major depressive disorder (MDD) and with antidepressant-induced mania. This study investigated a possible association with treatment-emergent insomnia or agitation. Methods: Thirty-six outpatients with MDD were genotyped at 5HTTLPR and treated with open-label fluoxetine up to 60 mg/day. Treatment-emergent adverse effects were assessed at each study visit. Results: Of nine subjects homozygous for the "S" allele, seven (78%) developed new or worsening insomnia, versus 6 of 27 (22%) non-"S"-homozygous subjects (Fisher's exact p = .005). Similarly, six of nine subjects homozygous for the "S" allele (67%) developed agitation, versus 2 of 27 (7%) of non-"S"-homozygous subjects (Fisher's exact p = .001). Conclusions: The "S" allele of the 5HTTLPR may identify patients at risk for developing insomnia or agitation with fluoxetine treatment. This preliminary result requires confirmation in larger samples.

AB - Background: The short (S) allele of the serotonin transporter gene-linked polymorphic region (5HTTLPR) has been associated with poorer antidepressant response in major depressive disorder (MDD) and with antidepressant-induced mania. This study investigated a possible association with treatment-emergent insomnia or agitation. Methods: Thirty-six outpatients with MDD were genotyped at 5HTTLPR and treated with open-label fluoxetine up to 60 mg/day. Treatment-emergent adverse effects were assessed at each study visit. Results: Of nine subjects homozygous for the "S" allele, seven (78%) developed new or worsening insomnia, versus 6 of 27 (22%) non-"S"-homozygous subjects (Fisher's exact p = .005). Similarly, six of nine subjects homozygous for the "S" allele (67%) developed agitation, versus 2 of 27 (7%) of non-"S"-homozygous subjects (Fisher's exact p = .001). Conclusions: The "S" allele of the 5HTTLPR may identify patients at risk for developing insomnia or agitation with fluoxetine treatment. This preliminary result requires confirmation in larger samples.

KW - Adverse event

KW - Agitation

KW - Depression

KW - Fluoxetine

KW - Insomnia

KW - Serotonin transporter

UR - http://www.scopus.com/inward/record.url?scp=0142157564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142157564&partnerID=8YFLogxK

U2 - 10.1016/S0006-3223(03)00424-4

DO - 10.1016/S0006-3223(03)00424-4

M3 - Article

VL - 54

SP - 879

EP - 883

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 9

ER -